![](https://startllc.com/wp-content/uploads/2024/01/Sequana-300x150.jpg)
Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure
DSMBi rates DSR 2.0 as safe following review of data from non-randomized cohort
Data from non-randomized cohort confirms dramatic improvement in diuretic response and at least 95% reduction in loop diuretic requirements up to almost four months after last DSR therapy
First patient enrolled in randomized controlled cohort expected in Q1 2024